Alps Advisors Inc Affimed N.V. Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$0.66 - $1.29 $1,938 - $3,788	-2,937 Reduced 2.96%	96,151 $72,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $21,397 - $47,657	19,452 Added 24.43%	99,088 $122,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $13,582 - $23,007	-6,930 Reduced 8.01%	79,636 $164,000
Q2 2022 Aug 11, 2022	SELL	$2.27 - $4.86 $82,977 - $177,652	-36,554 Reduced 29.69%	86,566 $240,000
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $56,995 - $87,269	-15,446 Reduced 11.15%	123,120 $538,000
Q4 2021 Feb 09, 2022	SELL	$5.37 - $7.07 $43,926 - $57,832	-8,180 Reduced 5.57%	138,566 $765,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $55,045 - $74,619	-9,936 Reduced 6.34%	146,746 $907,000
Q2 2021 Aug 11, 2021	BUY	$7.78 - $11.4 $145,758 - $213,579	18,735 Added 13.58%	156,682 $1.33 Million
Q1 2021 May 07, 2021	BUY	$5.12 - $8.48 $634 - $1,051	124 Added 0.09%	137,947 $1.09 Million
Q4 2020 Feb 03, 2021	BUY	$3.16 - $7.03 $435,520 - $968,895	137,823 New	137,823 $802,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.